# EDGAR Filing Document

**Accession Number:** 0001513525
**File Stem:** 0001213900-25-121686
**Filing Date:** 2025-12
**Character Count:** 3303
**Document Hash:** 8bc6e42e83da6d8fb90a7020cff2c6ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-121686.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001213900-25-121686

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADIAL PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001513525
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 800667150
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1180 SEMINOLE TRAIL
- **STREET 2:** SUITE 495
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22901
- **BUSINESS PHONE:** 434-422-9800

**MAIL ADDRESS:**
- **STREET 1:** 1180 SEMINOLE TRAIL
- **STREET 2:** SUITE 495
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22901

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADial Pharmaceuticals, L.L.C.
- **DATE OF NAME CHANGE:** 20170515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adial Pharmaceuticals, L.L.C.
- **DATE OF NAME CHANGE:** 20110218

![](image_001.jpg)

**Adial Pharmaceuticals, Inc.<br> 4870 Sadler Road, Suite 300<br> Glen Allen, Virginia 23060** 

**(310) 988-0643**

December 15, 2025

***<u>VIA EDGAR</u>***

United States Securities and Exchange Commission<br> Division of Corporation Finance

100 F Street, N.E.<br> Washington, D.C. 20549

Attention: Jason Drury

---

| | |
|:---|:---|
| **Re:** | **Adial Pharmaceuticals, Inc.**<br> **Registration Statement on Form S-3**<br> **Filed on December 12, 2025**<br> **File No: 333-292110**<br> **Request For Acceleration** |

---

Dear Mr. Drury:

Adial Pharmaceuticals, Inc. (the "**Registrant**") hereby requests that the United States Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-292110) (the "**Registration Statement**"), to become effective on **Wednesday, December 17, 2025, at 4:00 p.m**., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Staff of the Commission will consider this request for acceleration of the effective date of the Registration Statement as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws, including the Securities Act of 1933, as amended, as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick Egan, Esq. of Blank Rome LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Mr. Egan at (212) 885-5346 with any questions you may have concerning this request, and please notify either Ms. Marlow or Mr. Egan when this request for acceleration has been granted.

---

| |
|:---|
| Very truly yours, |
| **ADIAL PHARMACEUTICALS, INC.** |

---

---

| | |
|:---|:---|
| By: | /s/ Cary J. Claiborne |
|  | Name: Cary J. Claiborne |
|  | Title: President and Chief Executive Officer |

---

cc: Vinay Shah, Chief Financial Officer, Adial Pharmaceuticals, Inc. <br> Leslie Marlow, Esq. and Patrick J. Egan, Esq., Blank Rome LLP